China Unlikely To Be Included In US FDA's Project Orbis In The Near Term
Executive Summary
Oncology Center of Excellence Director Pazdur says there must be confidence that confidentiality agreements are universally accepted in response to request that China be included in the multi-regulator application assessment program.
You may also be interested in...
Drug Review Times Are Not Shortened Much By Single Expedited Review Designation
Government Accountability Office also finds that US FDA review divisions are largely consistent in their assessment times after controlling for goal dates and expedited programs.
Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
Novel Virus Brings Novel Threats To Global Pharmaceutical Manufacturing
As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.